360° UPSC Mains Analysis

Manila, Philippines

Manila experiences a tropical wet and dry climate (Köppen Aw) and is highly prone to typhoons and seismic activity due to its location on the Pacific Ring of Fire. India's climate is dominated by the tropical monsoon system, while the US spans temperate, subtropical, and arid zones.

The geographical context spans the Indo-Pacific maritime corridor, linking South Asia (India), Southeast Asia (the Philippines as a diplomatic venue), and North America (United States). Manila's coastal position on Manila Bay connects it directly to the South China Sea, a critical choke point for global trade.

India is a global pharmaceutical powerhouse, often termed the 'pharmacy of the world,' relying on key industrial clusters (such as Hyderabad and Baddi) for generic drug production. The US represents the primary export destination for these generics, making bilateral maritime trade routes across the Pacific and Indian Oceans economically vital.

The division of power under the Seventh Schedule of the Constitution of India places 'Foreign Affairs' (Entry 10), 'Diplomatic, consular and trade representation' (Entry 11), and 'Trade and commerce with foreign countries; import and export across customs frontiers' (Entry 41) under the Union List (List I). Consequently, the Central Government has exclusive legislative and executive competence to formulate trade policies, negotiate tariffs, and manage bilateral relations with the United States regarding pharmaceutical exports.

The US is India's top pharmaceutical export destination, importing around $8.7 billion worth of drugs in FY25. A 200% tariff will severely disrupt the bilateral trade balance, forcing India to seek trade negotiations or file disputes under the World Trade Organization (WTO) framework. It will accelerate the diversification of Indian exports towards other regulated and semi-regulated markets to offset the loss of the US market share.

The proposed US tariffs on generic drugs (rising to 100% in 2028 and 200% in 2029 after a 2-year grace period starting August 1, 2026) could impact India's export earnings, as the US is India's largest pharmaceutical export destination, accounting for over $8.7 billion in FY25. This could put pressure on India's current account deficit (CAD) and foreign exchange reserves if alternative markets are not secured. However, the immediate macro impact on GDP will be muted during the initial two-year zero-tariff grace period.

The secondary sector, specifically the pharmaceutical manufacturing industry, will face severe headwinds as India supplies approximately 40% of the US generic drug market. Indian generic drug manufacturers will see their profit margins squeezed or export volumes decline dramatically once the 100% and 200% tariffs kick in. This will force companies to either establish manufacturing facilities in the US or diversify their export destinations to regions like Europe, Africa, and Latin America.

The domestic pharmaceutical sector, which employs over 1.16 lakh people under the PLI scheme alone, could see a slowdown in job creation and potential layoffs in export-oriented units. Supply chains for active pharmaceutical ingredients (APIs) and formulations will face disruption as manufacturers adjust production capacities. Conversely, it may lead to a domestic oversupply of generic medicines, potentially lowering consumer prices for certain drugs within India.

The historical root of India's dominance in generic pharmaceuticals lies in the post-independence shift away from colonial-era patent laws. Under the British-era Indian Patents and Designs Act, 1911, product patents were recognized, which allowed foreign multinational corporations to monopolize the market and keep drug prices high. To address this, the Indian government sought to reform the patent regime to prioritize public health and domestic self-reliance.

Following the recommendations of the Justice N. Rajagopala Ayyangar Committee Report of 1959, India enacted the landmark Patents Act, 1970, which recognized only process patents (not product patents) for food, medicine, and chemicals. This allowed domestic manufacturers to legally reverse-engineer drugs and produce cheap generics, transforming India into the 'pharmacy of the world'. However, after joining the WTO in 1995, India amended its laws via the Patents (Amendment) Act, 2005, to comply with the TRIPS Agreement by reintroducing product patents, while retaining strict anti-evergreening safeguards like Section 3(d).

The current trade friction over US tariffs on Indian generics mirrors the long-standing bilateral tensions over Intellectual Property Rights (IPR). For decades, the US Trade Representative (USTR) has placed India on its 'Special 301' Priority Watch List, criticizing India's patent laws (specifically Section 3(d)) as being trade-restrictive. Similarly, the US termination of India's benefits under the Generalized System of Preferences (GSP) in 2019 highlighted how trade tariffs are historically leveraged by the US to pressure India on market access and IPR compliance.

The quest for self-reliance in pharmaceuticals is deeply rooted in the Swadeshi movement of the early 20th century. Acharya Prafulla Chandra Ray established Bengal Chemicals & Pharmaceutical Works in 1901 to challenge the British monopoly on essential drugs, establishing a precedent for indigenous drug manufacturing.

Pharmaceutical manufacturing, particularly Active Pharmaceutical Ingredients (APIs) and bulk drug synthesis, is classified as a 'Red Category' industry by the Central Pollution Control Board (CPCB) under the Environment (Protection) Rules, 1986. The discharge of untreated or inadequately treated chemical effluents containing heavy metals and solvents severely contaminates local water bodies, soil, and groundwater in major manufacturing hubs like Patancheru (Telangana) and Baddi (Himachal Pradesh). This leads to severe ecological degradation, rendering surrounding agricultural lands unproductive and disrupting local aquatic ecosystems.

The release of sub-lethal concentrations of antibiotics into the environment from pharmaceutical manufacturing effluents accelerates the selection pressure on bacteria, leading to the rapid emergence and spread of Antimicrobial Resistance (AMR) and 'superbugs'. Advanced wastewater treatment technologies, such as Zero Liquid Discharge (ZLD) systems, membrane bioreactors, and advanced oxidation processes, are critical to removing persistent organic pollutants and active pharmaceutical ingredients (APIs) before discharge.

The pharmaceutical manufacturing sector is highly energy-intensive, relying heavily on fossil fuels for chemical synthesis, heating, ventilation, and air conditioning (HVAC) systems. A shift in manufacturing locations (e.g., reshoring to the US due to tariffs) alters global supply chain logistics, potentially increasing or decreasing transport-related carbon emissions. Furthermore, the transition of manufacturing to countries with different energy mixes (e.g., US vs. India) directly impacts the carbon footprint of global generic drug production, influencing commitments under the Paris Agreement and Nationally Determined Contributions (NDCs).

The environmental footprint of pharmaceutical manufacturing directly impacts SDG 6 (Clean Water and Sanitation) by contaminating freshwater resources with toxic effluents and APIs. It also affects SDG 3 (Good Health and Well-being) through the proliferation of drug-resistant pathogens (AMR) and SDG 12 (Responsible Consumption and Production) by highlighting the need for green chemistry and sustainable chemical management in global supply chains.

A steep rise in tariffs directly threatens patients' access to affordable healthcare, potentially forcing them to ration or forego essential medications, which compromises their right to health and dignity. For Indian pharmaceutical workers, a drop in US demand could lead to wage cuts, layoffs, and reduced household income, directly impacting their standard of living.

Under the Constitution of India, Article 21 (Right to Life) has been judicially interpreted to encompass the right to health and affordable medical treatment. Internationally, Article 25 of the Universal Declaration of Human Rights (UDHR) recognizes the right to medical care as essential for an adequate standard of living, which is undermined by protectionist barriers on essential medicines.

The situation presents a conflict between national economic protectionism (the US prioritizing domestic manufacturing and jobs) and global health equity (ensuring universal access to affordable, life-saving medicines). It also highlights the tension between market-driven trade policies and the moral obligation to protect vulnerable populations from prohibitive healthcare costs.

Low-income patients globally, particularly in the US, who rely on affordable Indian generic drugs for chronic illnesses, face heightened health risks due to potential price surges. Additionally, semi-skilled and contractual workers in India's export-oriented pharmaceutical manufacturing units face livelihood insecurity and potential job losses if export volumes decline.